Al Hawkins, a former CEO-in-Residence, has broad expertise in developing new biomedical companies based on technologies licensed and identified from universities, hospitals and federal labs.  He has spent his career at the intersection of academic institutions and start-up companies in the life sciences as an entrepreneur, fund manager, and university tech transfer officer.  As a CEO-in-Residence, Hawkins launched Milo Biotechnology, a Cleveland company developing therapies for muscular dystrophy.